P601 Can Amitriptylin improve the quality of life in patients with Crohn's disease?
Jigaranu A.O., Dranga M., Gavrilescu O., Popa I., Ungureanu I., Mihai C., Cijevschi-Prelipcean C.
University of Medicine and Pharmacy Gr. T. Popa, IASI, Gastroenterology, Iasi, Romania
It is well known the fact that patients with inflammatory bowel disease (IBD) have an impaired quality of life (QoL) and up to 30% use antidepressants. Even though antidepressants are used in the treatment of irritable bowel syndrome few studies were made to evaluate their potential benefits on IBD patients.
We performed a double blind placebo study. We included 30 patients with Crohn's Disease (CD), in clinical remission or with a mild disease. The patients received either Amitriptylin 50 mg/day or placebo and were followed for 6 months (baseline, 3 and 6 months). The subjects completed IBDQ32 questionnaire for the QoL and provided blood and stool samples on each visit.
Of the 30 participants, 15 were randomized to receive Amitriptylin and 15 placebo. 18 of the patients (60%) were male and the mean age was 39.2 years. Amitriptylin had statistical significant effect on the social (60% vs 20%), emotional (66% vs 26%) and systemic (40% vs 20%) function in comparison with placebo. There was no effect of Amitriptylin on CD activity or on the faecal calprotectin levels.
Patients with CD in clinical remission or with a mild disease could improve the QoL after the administration of Amitriptylin.